Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy?
(2013) Urology — Vol. 81, n° 5, p. 998-1004 (2013)
Files
tombal-2013-ClinicalJudgmentversus.pdf
Restricted Access - Adobe PDF
- 181.92 KB
Details
- Authors
- Abstract
- Application of the BCJ together with PCA3 testing can reduce the number of repeat PBxs while maintaining the sensitivity to detect Gleason sum ≥7 PCa.
- Affiliations
Citations
Tombal, B., Andriole, G. L., de la Taille, A., Gontero, P., Haese, A., Remzi, M., Speakman, M., Smets, L., & Stoevelaar, H. (2013). Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy? Urology, 81(5), 998-1004. https://doi.org/10.1016/j.urology.2012.11.069 (Original work published 2013)